Version 2.78

Description

Avidity testing of Epstein Barr virus (EBV) capsid IgG is performed to differeniate between a primary and past infection. When B cells switch from the IgM to the IgG isotype in vivo, the first IgG antibodies produced are of low avidity. As IgG antibodies mature, B-cells end up producing IgG antibodies of relative higher avidities or binding strengths compared to early IgG antibodies. The IgG maturation process is usually completed within a few weeks after primary EBV infection. Measurements are obtained by EIA and a ratio is calculated between a patient's urea-treated and non-urea-treated samples to define the avidity index. PMID: 15297472 Source: Regenstrief LOINC, PMID: 15297472

Basic Part Properties

Part Name
Epstein Barr virus capsid Ab.IgG avidity
Part Display Name
Epstein Barr virus capsid IgG avidity
Part Type
Component (Describes the core component or analyte measured)
Created On
2012-01-02
Construct for LOINC Short Name
EBV IgG Avidity

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP145572-6

Language Variants Get Info

Tag Language Translation
pl-PL Polish (Poland) Wirus Epsteina Barr antygen kapsydowy Ab.IgG awidność
Synonyms: Awidność przeciwciał IgG do antygenu kaspydowego wirusa Epsteina-Barr